CU-264 | 1014006-50-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: CU-264
• 英文别名: 2-Amino-N-quinolin-8-yl-4-trifluoromethyl-benzenesulfonamide；2-amino-N-quinolin-8-yl-4-(trifluoromethyl)benzenesulfonamide
• CAS: 1014006-50-8
• 化学式: C₁₆H₁₂F₃N₃O₂S
• 分子量: 367.351
• InChiKey: RRBLHSDHBNSINM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  93.5
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  CU-264 在 亚硝酸特丁酯 、 溶剂黄146 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以23%的产率得到9-Trifluoromethyl-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide
  参考文献：
  名称：

  Novel Sulfonaminoquinoline Hepcidin Antagonists

  摘要：

  本发明涉及新型肝铁蛋白拮抗剂，包括它们的药物组合物以及将其用作药物治疗铁代谢紊乱，特别是铁缺乏病和贫血等疾病，特别是与慢性炎症性疾病相关的贫血。

  公开号：

  US20120214803A1
• 作为产物：
  描述：

  CU-265 在 tin(ll) chloride 作用下， 以 乙醇 为溶剂， 反应 2.0h， 生成 CU-264
  参考文献：
  名称：

  Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFκB activity within two separate high-throughput screens of NFκB activation

  摘要：

  We describe here a series of N-(quinolin-8-yl)benzenesulfonamides capable of suppressing the NF kappa B pathway identified from two high-throughput screens run at two centers of the NIH Molecular Libraries Initiative. These small molecules were confirmed in both primary and secondary assays of NF kappa B activation and expanded upon through analogue synthesis. The series exhibited potencies in the cell-based assays at as low as 0.6 mu M, and several indications suggest that the targeted activity lies within a common region of the NF kappa B pathway. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.10.100

文献信息

• Novel Sulfonaminoquinoline Hepcidin Antagonists
  申请人：Buhr Wilm

  公开号：US20120214803A1

  公开（公告）日：2012-08-23

  The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.

  本发明涉及新型肝铁蛋白拮抗剂，包括它们的药物组合物以及将其用作药物治疗铁代谢紊乱，特别是铁缺乏病和贫血等疾病，特别是与慢性炎症性疾病相关的贫血。
• COMPOUNDS THAT INHIBIT NFKB AND BACE1 ACTIVITY
  申请人：Landry Donald W.

  公开号：US20120064099A1

  公开（公告）日：2012-03-15

  The present invention relates to compounds with activity as BACE1 and NFκB modulators, and methods for treating, preventing, or ameliorating neurodegenerative diseases, such as Alzheimer's disease. The present invention is also directed to the treatment of diseases related to dysfunction of cell proliferation, the immune system and/or inflammation using such compounds or pharmaceutical compositions containing such candidate compounds.

  本发明涉及具有BACE1和NFκB调节剂活性的化合物，以及治疗、预防或改善神经退行性疾病（如阿尔茨海默病）的方法。本发明还涉及使用这些化合物或含有这些候选化合物的药物组合物治疗与细胞增殖功能障碍、免疫系统和/或炎症相关的疾病。
• Sulfonaminoquinoline hepcidin antagonists
  申请人：Vifor (International) AG

  公开号：US09102688B2

  公开（公告）日：2015-08-11

  The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.

  本发明涉及新型的赫普西丁拮抗剂，包括它们的药物组合物和将其作为药物用于治疗铁代谢紊乱的用途，特别是铁缺乏症和贫血，特别是与慢性炎症性疾病相关的贫血。
• NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS
  申请人：Vifor (International) AG

  公开号：EP2675526B1

  公开（公告）日：2017-02-01
• US20140275165A1
  申请人：——

  公开号：US20140275165A1

  公开（公告）日：2014-09-18